Time from melanoma diagnosis to surgery is commonly delayed in Medicare patients
the ONA take:
Surgery is delayed in 1 in 5 Medicare patients with melanoma, according to a Yale study. Melanoma is the leading cause of new cancer diagnoses in the United States.
In this population-based analysis of delay of surgery among Medicare patients with melanoma, culled from the Surveillance, Epidemiology, and End Result-Medicare database, the researchers reviewed more than 32,000 cases of melanoma diagnosis in Medicare patients.
No gold standard exists on time from diagnosis to study; however, the recommended timeframe from between diagnosis and surgery is less than 6 weeks.
This study found that 22% of patients waited longer than 1.5 months for surgery, and surgery was delayed more than 3 months in 8% of patients. Delays were most common when the treating clinician was not a dermatologist (eg, a primary care physician or general surgeon).
In addition, study findings revealed a significant difference in timing from melanoma diagnosis to surgery for Medicare patients.
The researchers suggest further studies should seek to identify reasons for the delay to surgery and to consider how coordination between care providers can be improved.
Surgery is delayed in 1 in 5 Medicare patients with melanoma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|